Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Immune checkpoint inhibitors (ICIs) are increasingly used as bridging or downstaging therapy before liver transplantation (LT) for hepatocellular carcinoma (HCC), but biomarkers of posttransplant recurrence in this setting are lacking. We evaluated the association between pretransplant plasma soluble programmed death-1 (sPD-1) and posttransplant outcomes after pretransplant ICI therapy.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
